Opinion & analysis

GSK And Pfizer Start Consumer JV For Different Reasons, Aim For Similar Goals

GlaxoSmithKline PLC and Pfizer Inc. agreed to an all-equity deal that sees the two pharma giants teaming up for a consumer healthcare product joint venture. Explore the ins and outs of the deal, and how it positions both GSK and Pfizer, as each are looking to raise investor confidence.

Get a more in-depth analysis on Pharmaceutical market trends with our Opinion on Analysis reports.

GSK And Pfizer Start Consumer JV For Different Reasons, Aim For Similar Goals

Infant Formula Production Stalls On Reckitt Benckiser’s Latest Stumble

Regulatory headaches: Brexit’s not the only thing you need to worry about

Interventional Neurology: Cerebral Aneurysm and Arteriovenous Malformation Systems

AbbVie’s Skyrizi Poised To Enter Packed Psoriasis Market

Commission Would Back Limited Expansion Of Products Covered By MDR Grace Period

Immuno-Oncology: Unicorns, China And The Perfect Storm

J.P. Morgan 2019: Industry Throws A Bonanza, With An Elephant In The Room

Serious Skin Reactions Reported with Ibuprofen Use in Europe

FDA Ban On Flavoring Ingredients Should Prompt Removal From Fragrances – WVE

Sterilization Facility Shutdowns Could Spell Medical Device Shortage; FDA Urges Firms To Assess ‘Downstream Impacts’

‘Project Orbis’ Oncology Pilot Eventually Will Target ‘Major Impact’ Applications

Goodbye To All That: EMA Leaves London After 24 years

FDA’s Quality System Regulation Is Mapped To International Standard ISO 13485 – And Vice Versa – In New Report From AAMI

US FDA May Largely Avoid House Democrats’ Investigation Agenda